The forecast data indicates a steady increase in pancreas malignant neoplasms mortality rates in the US from 2024 to 2028, rising from 15.0 to 15.9 deaths per hundred thousand persons. Comparing the year-on-year growth, there is an annual increase by approximately 1.3% to 1.4%. The compound annual growth rate (CAGR) over the five-year period is consistent at around 1.3%. In 2023, the mortality rate was recorded slightly lower, showing an ongoing upward trend.
Future trends to monitor include advancements in early detection and treatment options, which could potentially alter the projected growth in mortality rates. Attention should also be given to demographic shifts and healthcare policy changes that might impact these statistics.
